Comparative Pharmacology
Head-to-head clinical analysis: PMB 400 versus THEELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PMB 400 versus THEELIN.
PMB 400 vs THEELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PMB 400 is a combination of progesterone and micronized estradiol; progesterone suppresses gonadotropin secretion and transforms proliferative endometrium into secretory endometrium, while estradiol replaces endogenous estrogen production and promotes growth of reproductive tissues.
Estrogen receptor agonist; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and promoting estrogenic effects.
1 tablet (400 mg Pregabalin, 400 mg Mirogabalin, 100 mg Benfotiamine) orally once daily.
Intramuscular: 0.22 to 1.1 mg (220 to 1100 mcg) once weekly for menopausal symptoms; 0.5 to 2 mg (500 to 2000 mcg) once weekly for prostatic carcinoma.
None Documented
None Documented
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may be prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 13–19 hours (mean 16 h); clinical context: supports once-daily dosing for estrogen replacement.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism via CYP3A4 produces inactive metabolites, with biliary/fecal excretion of metabolites (20-30%) and parent compound (<5%).
Renal: ~50% as glucuronide and sulfate conjugates; fecal: ~30% via enterohepatic recirculation; biliary: ~20%.
Category C
Category C
Estrogen/Progestin Combination
Estrogen